JMT206 injections for obesity: safety and tolerability in adults with BMI 30+

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial explores multiple doses of JMT206 injected under the skin in adults ages 18 to 65 with a BMI of 30 or higher. Participants are randomly assigned to receive JMT206 or a placebo, with comparator semaglutide included as an active reference in the trial design. The study focuses on safety and tolerability over a defined dosing period, collecting information on adverse events, vital signs, and laboratory tests. The goal is to understand initial safety signals and determine suitable dose ranges for future studies. Location for enrollment is Peking University People’s Hospital in Beijing, with Shanghai JMT-Bio Inc. as the sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18\~65 (including threshold values), male or female participants;
2. BMI ≥ 30 kg/m²;
3. Weight change \<5% within the 3 months prior to screening
4. Voluntarily sign the informed consent form before the trial..

Exclusion Criteria:

1\) Those known to have a history of allergy to any component or related preparations in the investigational drug and its excipients, or have severe allergic diseases or allergic constitution; 2) Participants with a history of diabetes mellitus or hypoglycemic episodes; 3) Obesity is related to medication or diseases; Or weight gain caused by non-fat content; or monogene mutationsobesity; 4) History of weight loss surgery and/or treatment within the past year; 5) History of severe gastrointestinal disease or gastrointestinal surgery, clinically significant gastric emptying abnormalities, or long-term use of medications directly affecting gastrointestinal motility; 6) Having comorbidities known to affect skeletal muscle proteins; 7) A history of acute or chronic pancreatitis; 8) Acute gallbladder disease within one year prior to screening; 9) Previous or family history of medullary thyroid carcinoma or type 2 endocrine adenomatosis; 10) Severe cardiovascular or cerebrovascular events within 6 months prior to screening; 11) Any type of treated or untreated malignant tumor within 5 years prior to screening; 12) History of severe mental illness; 13) Use of drugs or products that may cause weight changes within 3 months prior to screening; 14) Use of drugs or products affecting skeletal muscle synthesis within 3 months prior to screening; 15) Participants deemed otherwise unsuitable for this trial by the investigator.

\-

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Clinical Trials Information Group officer
• Email: ctr-contact@mail.ecspc.com
• Phone: 86-0311-69085587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Menopause Experiences Across Cultures in Primary Care

  This observational study in Tarragona will see how menopause affects quality of life and how culture influences experiences, by surveying healthcare professionals and interviewing women from diverse backgrounds.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Tarragona · NCT07648680

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.